TDRD3: A Potential Drug Target and Biomarker (G81550)

Target Name: TDRD3

NCBI ID: G81550

TDRD3

TDRD3: A Potential Drug Target and Biomarker

TDRD3, short for Tudor domain containing 3, is a gene that has been identified as a potential drug target and biomarker for a variety of diseases. The Tudor domain is a unique genetic region that has been found to be highly conserved across various organisms and has been implicated in a number of cellular processes. One of the most interesting aspects of the Tudor domain is its potential role in disease, particularly in neurodegenerative diseases.

In neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, the Tudor domain is expressed in the brain and has been implicated in the development and progression of these diseases. The TDRD3 gene has been shown to be highly expressed in the brains of individuals with Alzheimer's disease and has been shown to be associated with increased levels of the neurotransmitter beta-amyloid in the brain. This suggests that TDRD3 may be a potential drug target for these diseases.

In addition to its potential role in neurodegenerative diseases, TDRD3 has also been shown to be involved in a number of other processes in the body. For example, TDRD3 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. TDRD3 has also been shown to be involved in the regulation of cell survival, which is crucial for the development and maintenance of tissues and organs.

In addition to its potential role in neurodegenerative diseases and its involvement in cell regulation, TDRD3 has also been shown to be a potential biomarker for a variety of diseases. For example, TDRD3 has been shown to be highly expressed in a variety of cancer tissues and has been used as a biomarker for cancer diagnosis and treatment. In addition, TDRD3 has been shown to be involved in the regulation of inflammation, which is a crucial aspect of many diseases including cancer.

Overall, the Tudor domain containing 3 (TDRD3) gene has a number of potential functions in the body, including its role in the regulation of cell adhesion, cell survival, and inflammation. As a result, TDRD3 is a promising candidate for a variety of diseases, including neurodegenerative diseases. Further research is needed to fully understand the role of TDRD3 in these diseases and to develop effective treatments.

Protein Name: Tudor Domain Containing 3

Functions: Scaffolding protein that specifically recognizes and binds dimethylarginine-containing proteins. In nucleus, acts as a coactivator: recognizes and binds asymmetric dimethylation on the core histone tails associated with transcriptional activation (H3R17me2a and H4R3me2a) and recruits proteins at these arginine-methylated loci. In cytoplasm, may play a role in the assembly and/or disassembly of mRNA stress granules and in the regulation of translation of target mRNAs by binding Arg/Gly-rich motifs (GAR) in dimethylarginine-containing proteins

The "TDRD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TDRD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets